The U.S. Food and Drug Administration has awarded two additional National Priority Vouchers under its Commissioner’s National Priority Voucher (CNPV) pilot program, signaling continued momentum behind the agency’s effort to accelerate review of products aligned with critical U.S. health priorities. The newly awarded vouchers were granted to investigational therapies targeting cardiovascular disease and oncology, with a stated emphasis on improving affordability and patient access.
With these awards, a total of 18 products have now received vouchers since the pilot program launched in June 2025, reflecting FDA’s increasing use of this mechanism as a policy tool to advance high-impact therapies.
Products Receiving the Vouchers
The vouchers were awarded to:
- Enlicitide decanoate, an oral PCSK9 inhibitor intended to lower LDL cholesterol and potentially expand access to cardiovascular therapies.
- Sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate under development for oncology indications.
FDA leadership highlighted the growing concern around healthcare costs and prescription drug pricing, noting that technological innovation alone is insufficient if patients cannot afford or access resulting therapies.
What the CNPV Program Is Designed to Do
The CNPV pilot program was established to significantly shorten FDA review timelines for investigational products that address one or more national priorities. These priorities include responding to public health crises, delivering innovative treatments for unmet medical needs, strengthening domestic manufacturing and supply chain resilience, and improving drug affordability and accessibility.
Voucher recipients benefit from enhanced communication with FDA review teams throughout development, with regulatory decisions targeted within one to two months following submission, compared to standard review timelines that typically extend much longer.
FDA recently announced its first completed review under the program, reporting substantial time savings relative to traditional pathways. This milestone suggests the program is transitioning from concept to operational execution.
Strategic Implications for Sponsors
The continued expansion of the CNPV program provides important insight into how FDA is prioritizing regulatory resources. In addition to innovation and unmet need, affordability and access are emerging as increasingly visible criteria for regulatory acceleration.
For sponsors, this underscores the importance of aligning development programs with broader policy objectives, including pricing strategy, manufacturing readiness, and public health impact. The program also highlights the value of early and proactive engagement with FDA to assess eligibility and optimize development timelines.
As more products move through the CNPV pathway, sponsors should expect heightened expectations around data quality, submission readiness, and operational execution, given the compressed review timelines.
How EMMA International Can Help
EMMA International supports organizations navigating accelerated regulatory pathways, including programs such as the CNPV pilot. Our services include regulatory strategy development, expedited program assessment, submission readiness planning, and support for FDA engagement across the product lifecycle.
As FDA continues to operationalize novel review mechanisms tied to national priorities, EMMA partners with sponsors to align development, manufacturing, and regulatory strategies to support both innovation and timely patient access.
Reference:
U.S. Food and Drug Administration. FDA News Release: FDA Grants Two National Priority Vouchers, December 19, 2025.
U.S. Food and Drug Administration. Commissioner’s National Priority Voucher Pilot Program Overview.
Federal Register. FDA Initiatives Supporting Accelerated Drug Development and Review.
